NEW YORK (GenomeWeb News) – Ventana Medical Systems today announced it is co-exclusively sublicensing certain patents and patents applications from Gen-Probe for the worldwide in vitro diagnostic rights to measure ERG protein expression by immunohistochemistry in prostate tissue.

Ventana, a Roche company, said that the license complements its existing worldwide co-exclusive sublicense under certain patents and patent applications for in situ hybridization for measuring ETS gene rearrangements, such as ERG gene rearrangements in tissue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.